Industry
Biotechnology
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
December 04, 2023 | 11:56 am
Portfolio Pulse from Benzinga Insights
November 27, 2023 | 2:00 pm
Portfolio Pulse from Benzinga Newsdesk
November 27, 2023 | 12:03 pm
Portfolio Pulse from Benzinga Newsdesk
November 14, 2023 | 1:29 pm
Portfolio Pulse from Benzinga Newsdesk
November 13, 2023 | 10:14 pm
Portfolio Pulse from Benzinga Newsdesk
October 12, 2023 | 11:18 am
Portfolio Pulse from Benzinga Newsdesk
October 05, 2023 | 8:34 am
Portfolio Pulse from Benzinga Newsdesk
October 03, 2023 | 8:40 pm
Portfolio Pulse from Bill Haddad
October 03, 2023 | 8:12 pm
Portfolio Pulse from Bill Haddad
October 03, 2023 | 8:12 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.